Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.

SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

AI biotechnology startup Valinor has raised $13 million in seed funding to further develop its multiomics-powered machine learning models to boost clinical trial success rates for drug development.

Lunit on Monday said it has started a collaboration with Daiichi Sankyo to use its artificial intelligence-based digital pathology tools to advance translational research and biomarker discovery for two of Daiichi's oncology pipeline programs.

Guardant Health announced Thursday that it has partnered with artificial intelligence firm Trial Library to expand access to cancer clinical trials across the US.

As part of promotional activities leading up to CACLP 2026, a series of activities took place successfully in Xiamen last week. Among them, the Xiamen Forum on Empowering the In Vitro Diagnostics Industry and Exploring New Models of Collaboration was held on 21 November 2025.

Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1tn market valuation, a sharp turnaround from this summer when its stock was hit by disappointing results for a new obesity pill.

Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine.

Following its announcement to return to Xiamen in 2026, CACLP has received overwhelming enthusiasm from exhibitors worldwide. As of October 2025, more than 1,000 companies have confirmed their participation for next year’s event, reaffirming CACLP’s role as the world‘s largest IVD event and an important annual gathering of the global diagnostic community.